Table 1.
Patient characteristics
| Case | Age | Sex | Histological classificationa | CPSb | HER2 | Pre-IC cTNMc |
Pre-IC cStagec |
Post-IC ycTNMd |
Post-IC ycStaged |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | M | por2 > > sig | CPS < 1 | Negative | T4bN0M0 | IVA | T3N0M0 | IIB |
| 2 | 65 | M | por2 > por1 + tub2 | 1 < CPS < 5 | Negative | T4aN2M0 | III | T4aN1M0 | III |
| 3 | 81 | M | por1 | CPS ≥ 5 | Negative | T4aN2M0 | III | T4aN1M0 | III |
| 4 | 60 | M | por1 > > tub2 | not examined | Negative | T4bN0M0 | IVA | T4aN0M0 | IIB |
| 5 | 72 | M | por | CPS ≥ 10 | Negative | T4bN1M0 | IVA | T3N0M0 | IIB |
por1 poorly differentiated adenocarcinoma, solid type, por2 poorly differentiated adenocarcinoma, non-solid type, sig signet-ring cell carcinoma, tub2 tubular adenocarcinoma, moderately differentiated type, CPS combined positive score, HER2 human epidermal growth factor receptor 2, IC induction chemotherapy
aHistological classification: Japanese classification of gastric carcinoma, 3rd English edition [23]
bCPS: score of programmed cell death ligand 1 expression in tumors, calculated by immunohistochemistry
ccTNM/cStage: clinical classification according to the Union for International Cancer Control TNM classification of malignant tumours, 8th edition
dycTNM/ycStage: clinical classification after perioperative therapy according to the Union for International Cancer Control TNM classification of malignant tumours, 8th edition